Last reviewed · How we verify
NCT05042934
Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
Phase 1, PHASE2 trial testing Fine-Needle Aspiration in Metastatic Ewing Sarcoma. Withdrawn.
30 August 2022
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 15 September 2021 |
| Primary completion | 30 August 2022 |
| Estimated completion | 30 August 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fine-Needle Aspiration
- Irinotecan (irinotecan) — full drug profile →
- Irinotecan Hydrochloride (Irinotecan Hydrochloride) — full drug profile →
- Lurbinectedin (LURBINECTEDIN) — full drug profile →
Conditions studied
- Metastatic Ewing Sarcoma — all drugs for Metastatic Ewing Sarcoma →
- Recurrent Ewing Sarcoma — all drugs for Recurrent Ewing Sarcoma →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
16 and older, any sex, with Metastatic Ewing Sarcoma or Recurrent Ewing Sarcoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase Ib/II trial studies best dose and side effects of lurbinectedin and how well it works with or without irinotecan in treating patients with Ewing sarcoma that has come back (relapsed) or is high risk and has spread to other places in the body (metastatic). Lurbinectedin may decrease chemicals in the body related to Ewing sarcoma, and reducing these chemicals may make the tumor cells more sensitive to irinotecan. Chemotherapy drugs, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving lurbinectedin with or without irinotecan may work better in treating patients with Ewing sarcoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies.
Sánchez-Molina S, Figuerola-Bou E, Sánchez-Margalet V, de la Cruz-Merino L, et al · · 2022 · cited 7× · PMID 36358891 · DOI 10.3390/cancers14215473
Verify or expand the search:
- PubMed search for NCT05042934
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fine-Needle Aspiration
Trials testing the same drug.
- NCT04185337 — Ultrasound-Guided Photoacoustic Imaging for the Detection of Metastases in Inguinal Lymph Nodes · EARLY_PHASE1 · completed
- NCT03578224 — Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer · EARLY_PHASE1 · completed
Other recruiting trials for Metastatic Ewing Sarcoma
Currently open trials in the same condition.
- NCT06820957 — Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has S · Phase 2, PHASE3 · active not recruiting
- NCT02243605 — Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma · Phase 2 · active not recruiting
- NCT02306161 — Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma · Phase 3 · active not recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05042934 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 10 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05042934.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing